Why attend?
As the CMS introduces new guidance for RWD studies, the FDA announces a RWE Center to promote its use in regulatory decision-making, and RWD becomes more accessible, investment is pouring into RWE generation. It is evident RWE will play an increasingly pivotal role in the drug development lifecycle, but questions still remain for the experts optimizing and applying RWE.
As the only industry meeting uniting RWE experts, the 13th IMPACCT Real-World Evidence Summit offers you the unique opportunity to consolidate, innovate and optimize your RWE strategy at all stages of the drug development lifecycle.
